For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
Bicara and DualityBio will soon test market appetite for new oncology issues.
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
